Last updated: November 29, 2023
Sponsor: University of Valladolid
Overall Status: Active - Recruiting
Phase
N/A
Condition
Osteomyelitis
Treatment
Placebo force hip lateral distraction
High force hip Lateral distraction
Clinical Study ID
NCT05712486
CASVE-NM-22-623
Ages 18-40 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Athletes diagnosed with osteitis pubis stage 1 with at least 3 months of evolution.
- Internal rotation ROM limited.
- Positive provocation pain tests.
Exclusion
Exclusion Criteria:
- Pain due to intraarticular hip pathology.
- Hip pain due to inflamatory diseases.
- Previous surgical interventions in hip, pelvis or lumbar spine.
- MRI results or provocation pain tests inconcluyent.
Study Design
Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Placebo force hip lateral distraction
Phase:
Study Start date:
February 01, 2023
Estimated Completion Date:
September 30, 2024
Connect with a study center
Silvia Lahuerta Martín
Soria,
SpainActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.